MARKET

SRRA

SRRA

SIERRA ONCOLOGY
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.52
-0.31
-2.59%
Closed 16:00 07/10 EDT
OPEN
11.72
PREV CLOSE
11.83
HIGH
11.78
LOW
11.49
VOLUME
9.20K
TURNOVER
--
52 WEEK HIGH
26.80
52 WEEK LOW
8.55
MARKET CAP
119.76M
P/E (TTM)
-0.4455
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SRRA stock price target is 32.67 with a high estimate of 48.00 and a low estimate of 16.00.

EPS

SRRA News

More
Sierra Oncology, Inc. (SRRA): Hedge Funds In Wait-and-See Mode
Insider Monkey · 06/26 16:44
Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · 06/18 17:00
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
GlobeNewswire · 06/16 21:05
Sierra Oncology's momelotinib shows long-term benefit in myelofibrosis
Seeking Alpha - Article · 06/12 14:12
Sierra Oncology Earlier Reported Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
- Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib - - Long-term tolerability
Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib - - Long-term tolerability · 06/12 13:01
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
PR Newswire · 06/12 07:30
Sierra Oncology Announces Presentations at Upcoming Investor Conferences
PR Newswire · 05/27 12:00
New CEO at Sierra Oncology
Seeking Alpha - Article · 05/26 12:11

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About SRRA

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
More

Webull offers kinds of Sierra Oncology Inc stock information, including NASDAQ:SRRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRRA stock methods without spending real money on the virtual paper trading platform.